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Abstract 
The Human Immunodeficiency Virus (HIV) infection is a major health problem worldwide 
estimated to affect about 34 million people. The hallmark of HIV pathogenesis is the gradual loss 
of the CD4+ T cell compartment along with a chronic state of immune hyperactivation. As 
infection progresses, HIV weakens the immune system to a level of profound immune 
dysfunction, which leads to the onset of Acquired Immunodeficiency Syndrome (AIDS)-related 
and non-related illnesses and ultimately to death if not treated. 
The introduction of Highly Active Antiretroviral Therapy (HAART) was an event of 
paramount importance for the treatment of AIDS. HAART allows, for the great majority of 
individuals, a substantial recovery of peripheral CD4+ T cell counts. As a result, morbidity and 
mortality among HIV infected patients has diminished enormously. However, a certain proportion 
of HIV infected individuals receiving HAART present poor immunological reconstitution even 
having undetectable viral load. These individuals are mentioned to as immunological non-
responders (InR) and, unlike full immunological-responders (IR), present increased risk of death. 
Several mechanisms have been proposed to explain immune reconstitution failure in HIV 
infected individuals. We have previously shown that a high proportion of regulatory T cells (Tregs) 
is associated with poor immune reconstitution. Here we further explored this observation and 
investigated if thymic activity, known to influence immune reconstitution, is also associated with 
poor immune reconstitution. Moreover, we analysed the interplay between thymic activity and 
Tregs and how is the relationship between them correlated with immune reconstitution. 
To analyse cells that have been recently exported by the thymus we defined a new gating 
strategy based on the CD31 expression by other cell types, namely granulocytes. Our results 
suggest that this strategy render the analysis of recent thymic emigrants (RTEs) more 
independent of the number and characteristics of CD4+ T cells. As expected, we observed that 
incomplete immune reconstitution is associated with lower thymic output in HIV infected 
individuals on HAART for at least one year. This is also the case for individuals with high 
percentages of Tregs. Interestingly, high percentages of Tregs are associated with low numbers 
of RTEs. Furthermore, increased counts of Tregs seem to result from an accumulation of 
CD45RA-CD4+ Tregs counts in the periphery and not from recently produced Tregs from the 
thymus. Dividing the cohort in three groups depending on the duration of the treatment and 
quality of the immune reconstitution, we observed that the IR show increased numbers of RTE as 
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compared with InR. Finally, Tregs seem to impact reconstitution during the first five years of 
treatment, specifically in individuals with higher percentages of Tregs. 
Altogether, this work sheds light of new evidences of an interplay between thymic activity 
and Tregs, which could have major implications in the outcome of the immune reconstitution in 
HIV infected individuals. 
 
Key words: HIV, HAART, Immune Reconstitution, Thymus, Recent Thymic Emigrants (RTEs), 
regulatory T cells (Tregs) 
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Resumo 
A infeção pelo Vírus da Imunodeficiência Humana (VIH) é um problema de saúde pública 
relevante, sendo estimado que 34 milhões de pessoas estejam infetadas a nível mundial. A 
patogénese do VIH é caracterizada pela redução progressiva no número de linfócitos T CD4+ em 
concomitância com um estado excessivo de ativação imune. Durante a progressão da doença, o 
VIH enfraquece e induz a disfunção do sistema imunitário em indivíduos infetados, o que leva ao 
aparecimento de doenças características da Síndrome da Imunodeficiência Adquirida (SIDA) e à 
morte, se não tratados. 
A introdução da Terapia Anti-Retroviral Altamente Ativa (TARV) foi um enorme progresso 
para o tratamento da SIDA. A TARV permitiu para a grande maioria dos indivíduos, uma 
recuperação substancial no número periférico de linfócitos T CD4+, o que resultou num 
descréscimo acentuado da mortalidade e morbidade entre indivíduos infetados com VIH. 
Contudo, alguns indivíduos infetados e em tratemento apresentam fraca reconstituição 
imunitária, mesmo com uma carga viral em níveis indetetáveis. Estes indivíduos, contrariamente 
aos com reconstituição imunitária adequada, apresentam um maior risco de morte. 
Vários fatores têm sido apontados como possíveis causas da fraca reconstituição 
imunitária em indivíduos infetados com VIH. Recentemente, o nosso laboratório verificou que 
elevadas percentagens de linfócitos T CD4+ reguladores (Tregs) estão associados à fraca 
reconstituição.  No presente estudo pretendemos não só confirmar esta observação prévia, como 
também explorar em que medida a atividade tímica está associada à reconstituição imunitária 
nos indivíduos com VIH. Adicionalmente, pretendemos também compreender como a atividade 
tímica e as Tregs se relacionam entre elas e influenciam conjuntamente a reconstituição. 
As células recentemente exportadas pelo timo (RTEs) expressam à sua superfície 
elevados níveis de CD31. Para estudar esta população definimos uma nova estratégia de análise 
em citometria de fluxo, com base na expressão de CD31 em granulócitos. Os nossos resultados 
sugerem que esta estratégia torna a análise de RTEs mais independente do número e 
características específicas dos linfócitos T CD4+. Como previsto, uma fraca reconstitutição está 
associada à baixa atividade tímica em indivíduos infetados com VIH com, pelo menos, um ano 
de terapia. Esta associação é também evidente em indivíduos com elevadas percentagens de 
Tregs. É interessante constatar ainda que elevadas percentagens de Tregs estão associadas a 
um baixo número de RTEs. Adicionalmente, verificamos que o aumento no número de Tregs 
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parece estar relacionado com uma acumulação no número de Tregs CD45RA-CD4+ na periferia, 
e não com o aumento de Tregs exportadas pelo timo. Após dividirmos o nosso coorte em três 
grupos, com base na duração do tratamento e na qualidade da reconstituição, observamos que 
os indivíduos com reconstituição imunitária adequada apresentam um número de RTEs 
aumentado, comparativamente com indivíduos com fraca reconstituição imunitária. Finalmente, 
as Tregs parecem influenciar a reconstituição durante os primeiros cinco anos do tratamento, 
nomeadamente em individuos com elevadas percentagens de Tregs. 
Em conclusão, este estudo sugere novas evidências para uma interação entre a atividade 
tímica e as Tregs, o que pode ter implicações relevantes no decorrer do processo de 
reconstituição imunitário em indivíduos infetados com VIH. 
 
Palavras-chave: VIH, TARV, Reconstituição Imune, Timo, Células Recentemente Exportadas 
pelo Timo (RTEs), linfócitos T CD4+ reguladores (Tregs) 
  
  
xiii 
Table of Contents 
1. Introduction ...................................................................................................................... 1 
1.1. The Human Immunodeficiency Virus (HIV) .................................................................... 1 
1.1.1. A Brief Overview: HIV Structure, Life Cycle and Prevalence of Infection ................... 1 
1.1.2. From HIV Pathogenesis to AIDS: How the Immune System Gets Sick ..................... 3 
1.1.3. Highly Active Antiretroviral Therapy (HAART): A Giant Leap for AIDS Treatment ...... 5 
1.1.4. Immune Reconstitution under HAART .................................................................... 6 
1.2. The Thymus ................................................................................................................. 8 
1.2.1. A Brief Overview: Structure and Function ............................................................... 8 
1.2.2. Age-Dependent Thymic Involution .......................................................................... 8 
1.2.3. Major Techniques to Assess Thymic Activity in Humans ......................................... 9 
1.3. Thymic Function in the Context of HIV Infection........................................................... 12 
1.3.1. Effects of HIV on Thymic Structure and Activity .................................................... 12 
1.3.2. Immune Reconstitution under HAART: is the Thymus Part of the Business?.......... 13 
1.4. Tregs in the Context of HIV Infection ........................................................................... 14 
1.4.1. Tregs in the Immune System: What’s their Purpose? ............................................ 14 
1.4.2. Regulatory T cells in Immune Reconstitution under HAART: Friends or Foes? ....... 15 
2. Aims ............................................................................................................................... 17 
3. Material and Methods ..................................................................................................... 19 
3.1. Study Participants ...................................................................................................... 19 
3.2. Flow Cytometry Analysis ............................................................................................. 19 
3.2.1. RTEs Characterization ......................................................................................... 19 
3.2.2. Tregs Characterization ........................................................................................ 19 
3.2.3. Flow Cytometry Data Analysis .............................................................................. 20 
3.3. Statistical Analysis ...................................................................................................... 20 
4. Results ........................................................................................................................... 21 
  
xiv 
4.1. A Novel Gating Strategy to Define Recent Thymic Emigrants (RTEs) ............................. 21 
4.2. Thymic Activity and Immune Reconstitution ................................................................ 25 
4.3. Tregs Percentages and Immune Reconstitution ........................................................... 26 
4.4. Thymic Activity and Tregs Percentages During Immune Reconstitution ........................ 30 
4.5. Thymic Export and Peripheral Tregs ............................................................................ 32 
4.6. Thymic Activity and Tregs in Different Immune Reconstitution Groups ......................... 33 
5. Discussion and Conclusions ............................................................................................ 39 
5.1. A New Gating Strategy to Define RTEs ......................................................................... 39 
5.2. Immune reconstitution and Tregs – The Definition of Clusters ..................................... 40 
5.3. Thymic Activity and Immune Reconstitution ................................................................ 40 
5.4. Tregs and Thymic Activity – Two (In)Dependent Factors Influencing Immune 
Reconstitution?................................................................................................................ 41 
5.5. Tregs and Thymic Activity in the Reconstitution Groups ............................................... 42 
6. References ...................................................................................................................... 45 
 
  
  
xv 
Abbreviations List 
AIDS  Acquired Immunodeficiency Syndrome 
CT  Computer Tomography 
FOXP3  Forkhead-Box Transcription Pactor P3 
GALT  Gut-associated Lymphoid Tissues 
HAART  Highly Active Antiretroviral Therapy 
HIV  Human Immunodeficiency Virus  
IL  Interleukine 
InR  Immunological non-Responders 
IR  Immunological Responders 
iTregs  Induced Regulatory T Cells 
MHC  Major Histocompatibility Complex 
nTregs  Naturally occurring Regulatory T Cells 
PBMCs  Peripheral Blood Mononuclear Cells 
RTES  Recent thymic Emigrants 
TCR  T Cell Receptors 
TRECs  T Cell Receptor Excision Circles 
Tregs  Regulatory T cells 
UNAIDS Joint United Nations Programme on HIV/AIDS 
WHO  World Health Organization  
  
xvi 
 
  
1 
 
1. Introduction 
1.1. The Human Immunodeficiency Virus (HIV) 
1.1.1. A Brief Overview: HIV Structure, Life Cycle and Prevalence of 
Infection 
The Human Immunodeficiency Virus (HIV) belongs to the Lentivirus genus of the 
Retroviridae family [1]. HIV was defined in 1983 as the etiological causative agent of the Acquired 
Immunodeficiency Syndrome (AIDS) disease and is classified into two major types: HIV-1 and 
HIV-2. HIV-1 is widely disseminated and accounts for the majority of infections worldwide (99%), 
being more virulent than HIV-2 whose disease progression occurs at a slower rate [1-3]. HIV-2 is 
more restricted to some areas in West Africa and some countries in Europe, with major incidence 
in Portugal, but its prevalence has been falling, maybe due to lower transmission efficiency [3].  
The HIV virion structurally comprises two identical single -stranded RNA molecules and the 
affiliated enzymes reverse transcriptase, integrase and protease, enclosed within a proteic 
nucleocapsid (consisting of an inner -core capsid (p24) and an outer-core matrix (p17) proteic 
layers) (Figure 1). Surrounding these structural elements is a roughly spherical outer 
phospholipid bilayer membrane envelope, derived from the host cell membrane after budding 
and release of the virion from an infected cell. Additionally, the viral envelope includes the 
transmembrane env complex which consists of a trimeric structure of three gp120/gp41 pairs of 
glycoproteins. This complex is the mediator of HIV cell entry by binding to CD4 molecule on 
target cells, with concomitant binding to the main chemokine co-receptors for HIV, CCR5 and 
CXCR4 [1, 4].  
 
Figure 1. Structure of HIV-1 virion and major constituents. Extracted from the website [5] 
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All HIV strains have the ability to infect CD4+ T cells, the major viral-receptor, but the 
ability of some strains to infect other cells relies on the specificity of gp120 variants to attach 
different chemokine receptors, which in turn determines the tropism of HIV strains as R5 (CCR5), 
X4 (CXCR4) or even R5/X4 tropic-viruses, for the virus that use one or both chemokine receptors 
[1, 6]. The major targets of HIV are CD4+ T cells, yet among other cells infected are 
macrophages, monocytes and dendritic cells.  
Once the virion fuses with host cell membrane, HIV RNA genome is released and reverse 
transcribed into double-stranded DNA by the enzyme reverse transcriptase (Figure 2). Then, both 
viral DNA and integrase enzyme enter the nucleus which leads to the integration of HIV DNA 
(provirus) into the cell host genome. The provirus can remain transcriptionally inactive during 
months or even years, establishing a latent infection [1]. 
 
Figure 2. HIV life cycle. Simplified view of the sequential steps of HIV life cycle, since HIV virion entrance into the host cell, 
until the release of a new virion. Extracted from the website [5]. 
When the infected cell is activated by an intrinsic (e.g. cytokines) or extrinsic (e.g. foreign 
antigen) stimuli, HIV gene transcription can be triggered leading to the production of HIV RNA 
transcripts. Thereafter, due to sequential and differential splicing events, first transcripts of 
regulatory genes and, afterwards, of structural genes are exported from the nucleus to the 
cytoplasm, translated into proteins and processed by the HIV protease. Finally, the assembly of 
new virions starts by packaging the HIV RNA transcripts and associated proteins within the 
nucleocapsid core, followed by the release of mature virions from the host cell by budding [1].  
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The most frequent route of HIV transmission is through sexual contact and occurs either 
between heterosexual couples or between male homosexual partners. Less frequent routes are 
vertical transmission from mother-to-child in utero, during childbirth or through breast-feeding; 
transmission among injection drug users that share needles; and contact/exposure to blood or 
blood products of HIV seropositive individuals during transfusions [1, 7]. 
At the end of 2010, the World Health Organization (WHO) and the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) estimated that there were 34 million people living with HIV 
worldwide (Figure 3) [8]. The infection continuous to be highly prevalent in the Sub-Saharan 
Africa with an alarming estimation of 23 million people infected (2/3 of global infections). This 
numbers renders HIV one of the major epidemic diseases worldwide and case of serious health 
concern. Although the number of people living with HIV is steadily increasing, the number of new 
HIV infections is decreasing [8]. The explanation relies on population awareness on HIV 
transmission and on the currently available antiretroviral drugs that increase life-expectancy of 
infected individuals (see section 1.1.3). 
In Portugal, at the end of 2011, the number of individuals reported to live with HIV/AIDS 
was 41 035, from which 80,9% were male and 19,1% female [9]. 
 
Figure 3. Estimated numbers of adults and children (all ages combined) infected and living with HIV in 2010. 
Figure extracted from the WHO Global Report 2011. 
1.1.2. From HIV Pathogenesis to AIDS: How the Immune System Gets Sick 
HIV pathogenesis is characterized by the gradual loss of the CD4+ T cell compartment 
(Figure 3) and by the chronic state of immune hyperactivation. By the time HIV establishes a 
productive cell infection (primary infection), the pathogenic progression of the disease begins with 
an acute infection phase characterized by high levels of viral replication, and a massive depletion 
  
4 
 
of CD4+ T cells, particularly in the gut-associated lymphoid tissues (GALT), where the majority of 
cells are memory activated CD4+CCR5+ T cells. While viral dissemination continues, allowing the 
seeding of other lymphoid tissues, especially the lymph nodes, both a humoral and cell-mediated 
immune responses retaliate against HIV [1, 2, 7, 10].  
 
Figure 4. Typical course of HIV disease progression in an untreated HIV infected individual. Extracted from [11]. 
Despite partial control and drop of plasma viremia 12 weeks after infection, the immune 
system fails to eliminate the resilient virus. HIV establishes persistent viral reservoirs in lymphoid 
tissues and in latently infected resting CD4+ T cells, leading to the chronic phase of the disease. 
This period can go on for several years, depending on the rate of disease progression, and is 
characterized by clinical latency of the disease. Regardless of some initial regenerative capacity, 
with rise in number of peripheral CD4+ T cells, ongoing viral replication, cell infection and death, 
and chronic immune activation, lead to progressive immune deficiencies [1, 2, 7, 10]. 
HIV-induced cell death of CD4+ T cells may be due to direct cythopathic effects of viral 
replication in infected cells or to immune surveillance of HIV-specific CD8+ cytotoxic T cells that 
kill infected cells (Figure 5), although natural killer (NK) cells can also exert some function [1, 2, 
10]. Furthermore, progression of the disease in the chronic phase is also marked by high levels 
of cell immune activation, proliferation, and production of inflammatory cytokines. This, 
detrimentally leads also to bystander effects of HIV by indirect instigation of activation-induced 
cell death (apoptosis) in uninfected cells [2, 7, 10], as it was described for naïve T cell death in 
lymphoid tissues [10]. 
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Figure 5. Schematic representation of different mechanisms involved in T cell death and turnover during HIV 
pathogenesis. Extracted from the website [5]. 
HIV preferentially infects CD4+ T cells which are key players in the adaptive immune 
system [10]. By destroying these cells during the course of infection, HIV weakens the immune 
system to a level of profound injury and immune dysfunction and exhaustion, rendering the onset 
of clinical AIDS when CD4+ T cells fall below 200 cells/μL. As the CD4+ T cell compartment gets 
compromised, eradication of opportunistic infections, and of a wide spectrum of characteristic 
diseases, is hampered [2]. However deleterious effects and immune dysfunction are extended to 
CD8+ T cells, NK cells, and B cells by mechanisms that induce nonspecific cell activation, 
turnover and differentiation. Nonlymphoid cells like macrophages and dendritic cells are also 
functionally impaired in their capacity to phagocytise and present antigens due to indiscriminate 
activation [2, 7, 10]. In addition, HIV seems to be responsible for the loss of mucosal integrity 
and concomitant microbial translocation, which contribute to immune activation [7], to reduced 
export of progenitor cells from the bone marrow [12] and for structural and functional alterations 
both in the thymus [13, 14] and in the lymph nodes [15]. 
Altogether, these quantitative and qualitative alterations and the loss of homeostasis, 
since the beginning of the infection and throughout the course of pathogenesis, inevitably 
culminate in the functional disability and “immune incompetence” of the immune system. 
1.1.3. Highly Active Antiretroviral Therapy (HAART): A Giant Leap for AIDS 
Treatment 
The introduction of Highly Active Antiretroviral Therapy (HAART) was an event of 
paramount importance for the treatment of AIDS and of the pathogenic progression of HIV.  
HAART regimens are usually a combination of drugs that, on one hand, inhibit viral 
replication by targeting viral proteins such as reverse transcriptase, protease and integrase and, 
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on the other hand blocks host’s membrane protein CCR5, impeding virus entrance into CD4+ T 
cells [16, 17]. By reducing plasma HIV-RNA viral copies to amounts below the detection levels, 
HAART also allows, for  the majority of treated individuals, a substantial recovery of peripheral 
CD4+ T cell counts [17]. Consequently, HAART has dramatically diminished morbidity and 
mortality among HIV infected individuals [16]. Nevertheless, HAART also embraces some 
problems like undesirable toxic side-effects and the associated elevated costs [16]. 
When is the best time to initiate HAART? This question has been widely discussed, due to 
both problems resulting from short- and long-term toxic effects of commencing HAART during 
early-stages of disease, and to the harmfulness evidences of untreated HIV infection [16]. The 
current guidelines in Europe [18] and in the USA [19] indicate initiation of therapy when CD4+ T 
cell numbers fall below 350 cells/μL. Nonetheless, this issue has been actively debated over 
time. In the beginning, the concept of hitting HIV early and hard, even when infected individuals 
were in early-stage disease (CD4+ T cell counts above 500 cells/μL), was considered to be the 
best approach [20]. With time, the emergence of HAART side-effects lead physicians to 
reconsider this strategy, by postponing HAART initiation. Nowadays, the therapeutic strategies are 
again changing to a more aggressive approach, due to the fact that the currently antiretroviral 
drugs used are considered safe and are well tolerated by the vast majority of patients, and due to 
the evidences that HAART prevents transmission [16]. However, in specific circumstances, 
HAART can be initiated regardless of CD4+ cell counts, such as in pregnant women, in patients 
with active viral hepatitis, coronary artery disease, history of an AIDS-defining illness and in HIV-
associated nephropathy [16, 19]. 
1.1.4. Immune Reconstitution under HAART 
After commencing HAART, immune reconstitution of the CD4+ T cell compartment is 
kinetically achieved, in most cases, in a biphasic fashion [17, 21]. During the first 2–3 months 
HIV viral load rapidly declines and CD4+ T cell numbers increase (Figure 6). This could be 
explained by the release or redistribution of memory CD4+ T cells from lymphoid tissues, such as 
the lymph nodes and GALT, due to decreased viral replication, which may contribute for cell 
entrapment. Simultaneously, the number of CD8+ T cells, of NK T cells and B cells augment and 
the levels of inflammatory cytokines [e.g. tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6], 
activation and apoptosis diminish [17]. The second phase proceeds for several years, and seems 
to rely on the regeneration of naïve CD4+ T cell compartment (Figure 6). This seems to be 
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explained by several processes, such as homeostatic peripheral expansion of pre-existing naïve 
and memory T cells, by increased cell life-span and by thymic export of new naïve T cells to the 
periphery, which is fundamental to augment the T cell repertoire diversity [17, 22]. Peripheral 
naïve CD4+ T cells also accumulate due to diminished conversion of naïve into memory cells, as 
a result of decreased loss of memory CD4+ T cells and decreased immune activation. 
Reconstitution continues beyond 10 years of HAART, although at a slower rate after 3 years of 
therapy [17].  
 
Figure 6. Biphasic kinetics and mechanisms associated with the reconstitution of the CD4+ T cell compartment 
after starting HAART. Extracted from [17]. 
Despite the successful introduction of HAART, a proportion of 17–40% of HIV infected 
individuals receiving HAART that are full viral responders, present poor immunological 
reconstitution, as measured by the gain in number of CD4+ T cells until reaching a plateau after 
4–5 years of HAART [17, 23, 24]. These individuals are mentioned to as immunological non-
responders (InR). The mechanisms underlying immune reconstitution failure remain to be fully 
explained. Among the causes that have been put forward to justify poor reconstitution [22, 23], 
are: impaired bone-barrow function; reduced thymic output; high percentages of CD4+ regulatory 
T cells (Tregs); high immune activation; ongoing residual viral replication; advanced age; long 
duration of HIV infection before HAART; low baseline CD4+ T cell count before HAART; co-
infections (e.g. Hepatitis C Virus); and gut microbial translocation. 
Our previous results suggest that the percentage of Tregs influences immune 
reconstitution (Horta et al. manuscript submitted for publication). Tregs might be from two 
origins: thymic origin (naturally occurring Tregs) or induced in the periphery (induced Tregs). 
Since the major goal of this work is to explore how Tregs and thymic activity correlate to each 
other in HIV infected individuals, from now on, the role of thymic activity and Tregs, the 
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relationship between these parameters and on how they could be influencing the immune 
reconstitution of HIV-1 infected individuals, are object of more detailed introduction. 
1.2. The Thymus 
1.2.1. A Brief Overview: Structure and Function 
The thymus is a mediastinal organ where new T cell differentiation takes place. This 
lobulated organ comprises two core elements, the thymic epithelial space and the non-epithelial 
perivascular space, both within the thymic capsule. The thymic epithelial space is an epithelial 
network, consisting on an inner medulla and an outer cortex, and it is where T cell differentiation 
(thymopoiesis) occurs. The perivascular space is the non-thymopoietic portion of the thymus 
located between the thymic epithelial space and the thymic capsule. It contains blood vessels 
and presents infiltrates of peripheral memory CD4+ and CD8+ T cells and of B cells [25-27].  
T cell lymphopoiesis starts by the migration of hematopoietic progenitor cells from bone-
marrow (or from the fetal liver during development) to the thymus, which provides a 
microenvironment of well-orchestrated stimuli that induces T-cell lineage commitment and 
differentiation [25, 28, 29]. During this process, T cell receptor (TCR) genes undergo sequential 
chromosomal rearrangements, so that functional and highly diverse TCRs are generated. 
Subsequently, thymocytes that express a mature TCR are selected to discriminate between self 
and non-self-antigens, first by recognizing antigens presented in the context of self-major 
histocompatibility complex (MHC, positive selection), and then thymocytes auto-reactive to self-
antigens are eliminated (negative selection) [27, 29]. The final mature thymocytes are exported 
to the periphery as newly generated naïve T cells [27], also called recent thymic emigrants 
(RTEs), to set up and enrich in diversity the peripheral T cell pool. 
1.2.2. Age-Dependent Thymic Involution 
The thymus is essential for setting up the peripheral T cell pool before birth and early in 
life, as children borned with congenital absence of the thymus (complete DiGeorge Syndrome) 
present severe defects in T cell production and function [26, 30]. 
The thymus undergoes an age-dependent involution associated with a decline in function 
and consequently, in thymopoiesis. Previously, it was thought that the end of puberty was a 
marker of the beginning of thymic involution, but currently it is known that the thymus begins its 
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age-associated involution after one year of age, at a rate of 3% of volume shrinkage until middle 
age (35-45 years of age), and of roughly 1% throughout the rest of the life. As age advances, the 
perivascular space becomes gradually expanded due to fat (adipocytes) accumulation, leading to 
the shrinkage of thymic epithelial space (medulla and cortex) (Figure 7) [25, 26]. 
 
Figure 7. Age-associated thymic involution. As individuals’ age advances, the thymic epithelial space that comprises both 
medulla (brown) and cortex (orange), which is responsible for thymopoiesis, starts to shrink due to the gradual and increasing 
accumulation of adipocytes (yellow) in the perivascular space. This process leads to a diminishment of the total thymic volume, of 
the thymic epithelial space and, consequently of the production and export of naïve T cells to the periphery over time. Extracted 
from the website [31].  
Although thymic activity descreases over time, it was reported the existence of thymic 
activity at least until the eight decade of life due to the presence of thymic epithelial islands of 
cortex and medulla in a 78 years-old woman [25]. In addition, since the late 1990’s, evidence 
emerged that there is an interplay between an age-dependent contribution of the thymus, by 
producing RTEs, and the peripheral expansion/proliferation of post-thymic T cells for the 
regeneration and preservation of the peripheral T cell pool. Thymus contibution seems to 
predominate mostly early in life, and peripheral expansion at later ages [14, 26].  
1.2.3. Major Techniques to Assess Thymic Activity in Humans 
Thymopoiesis in humans has been evaluated by several methods, mainly to assess 
thymic contribution during peripheral T cell reconstitution in some clinical settings, like during 
HIV infection. Frequently, the combination of different methods has been used to overcome 
technical limitations that each method comprises. 
A widely used technique for assessment of thymic activity is the quantification of signal-
joint T cell receptor excision circles (sjTRECs) by real-time quantitative polymerase chain reaction 
[14, 32-34]. TRECs are portions of episomal DNA excised during chromosomal rearrangements, 
when the TCR is formed in developing thymocytes, and are present only among naïve T cells. 
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TRECs are stable and do not duplicate during cell division/proliferation, so the higher the TREC 
frequency in a given population, the more immature are T cells and less proliferation they 
experienced [14]. Among the different TRECs formed, the sjTRECs (Figure 8A) are present in 
nearly 70% of RTEs, thus they have been used as surrogate markers of thymic output [14, 32-
34].  
 
Figure 8. Generation of TREC molecules and the sj/βTREC ratio. The sjTRECs are circular DNA molecules excised 
during chromosomal rearrangement of T cell receptor genes, at the TCRα locus, when the T cell receptors are being formed in 
the process of thymocyte maturation (A). DJβTRECs are generated early in thymopoiesis, previously to sjTRECs formation, and 
are diluted during intrathymic maturation of thymocytes undergoing clonal expansion, between late triple-negative (TN) and early 
double-positive (DP) stages (B). The sjTRECs generated later in thymopoiesis, in the DP stage. The thymocytes in the single-
positive stage (SP) harbour both types of TRECs that are quantified in the periphery by Real-time PCR to calculate the sj/β TREC 
ratio. Adapted from [35]. 
Nevertheless, in clinical cases such as in HIV infection, due to increased T cell 
proliferation in the periphery, TREC molecules dilute faster, resulting in an impaired association 
between sjTRECs frequency and thymic output, regardless of thymic activity. To overcome this 
problem Dion et al. [36] proposed the sj/β TREC ratio as a reliable estimate of intrathymic 
proliferation and thus of thymopoiesis, by taking into account the quantification of both sjTRECs 
and DJβ TRECs frequencies in the periphery (Figure 8B). Supporting this reliability is the fact that 
the sj/β TREC ratio is not significantly affected by extrathymic proliferation, and alike sjTRECs 
decreases with age [36]. 
Identification of cell surface molecules on RTEs by flow cytometry is another extensively 
used technique for routine assessment of thymic activity in the periphery or within thymic 
dissociated tissue [14, 32, 37-41]. At the end of last century, beginning of the XXI century, 
thymic activity was quantified by the percentage or number of naïve T cells, using CD45RA and 
CD62L as markers [14, 32]. However, naïve T cells are the sum of both thymic output and 
peripheral expansion. Nevertheless, in 2002 Kimmig et al. [38] first stated the use of CD31 [also 
known as platelet endothelial cell-adhesion molecule (PECAM-1)], within the naïve pool 
(CD45RA+) of CD4+ T cells as a correlate of thymic activity in the periphery (Figure 9).  
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Figure 9. Representation of mechanisms of post-thymic proliferation in human naïve CD4+ T cells. Extracted from 
[42]. 
CD4+ T cells that co-express CD31 and CD45RA have an average TREC frequency 8 
times higher than that of CD45RA+ CD4+ T cells lacking CD31 expression in healthy individuals 
[38]. This also highlighted the advantage of using CD31 instead of CD27 and CD62L (markers 
are expressed by the majority of CD45RA+ CD4+ T cells) to characterize naïve CD4+ T cells. By 
the level of  CD31 expression two different subpopulations can be distinguished within the naïve 
CD4+ T cell pool: one that already underwent homeostasis-driven peripheral expansion and lacks 
CD31; and another that has a more recent thymic origin due to higher TREC content and is 
CD31+ [38].  
More recently it was also described the use of protein tyrosine-kinase 7 (PTK7) as a cell 
surface marker for RTEs within peripheral naïve CD4+ T cells, for which antibodies are also 
available [43, 44]. However, the reports from two different groups showed substantially different 
results, concerning the percentages of PTK7 and so the potential of this marker to characterize 
RTEs needs to be further addressed.   
Analysis of T cell repertoire diversity might also be considered, although indirectly, as a 
way to evaluate thymic output, since a diverse peripheral T cell repertoire is indicative of thymic 
activity. This has been done via spectratype analysis of the complementary determining region 3 
(CDR3) length for each Vβ family of the TCR by PCR methods [30, 45]. Flow cytometry is also 
used to analyze diversity by determining TCRVβ usage [45]. 
Chest Computed Tomography (CT) scans are used to evaluate both thymic volume [46, 
47] and size [34, 48], since it has been shown a correlation between these parameters and 
thymic activity. However, this association has to be made with caution, as it does not furnish full 
insight about thymopoietic activity [13, 30]. Positron Emission Tomography (PET) is based on the 
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measurement of metabolic activity, by uptake of radiolabeled glucose, which has been also 
correlated with metabolically thymic activity [25].  
1.3. Thymic Function in the Context of HIV Infection 
HIV induces lymphopenia by depleting the CD4+ T compartment in HIV infected 
individuals. Since the thymus is the primary organ of T lymphopoiesis, it is of interest to address 
its’ role in the setting of HIV infection. The last 15 years provided a wealth of information 
regarding the role of thymus during HIV infection, but despite so much progress, the exact role of 
this organ during the process of immune reconstitution in HIV infected individuals remains a 
matter of controversy and investigation. 
1.3.1. Effects of HIV on Thymic Structure and Activity  
Besides the profound CD4+ T cell lymphopenia and chronic immune activation, thymic 
function seems also to be impaired during HIV infection, with reduced export of new T cells and 
changes in thymic structure. The thymic perivascular space is filled up and expands due to 
inflammatory infiltrates of macrophages, B cells, and CD8+ effector T cells, as shown by 
immunohistological analysis of thymuses from five HIV infected individuals, both treatment-naïve 
and on HAART [13]. Calcification of Hassall’s bodies and collapsed thymic epithelium, with 
extended areas lacking thymopoiesis on two of five individuals, also seem to be the result of HIV-
induced changes in thymic morphology [13]. Consequently, thymus atrophy increases at an 
accelerated rate, in comparison with natural age-related thymic involution. HIV-infected cells were 
also detected inside thymus, both early and in late stages of the disease [13, 32]. 
Impaired thymic function in HAART-naïve individuals was demonstrated by estimation of 
sj/β TREC ratio [36]. A rapid and profound suppression of intrathymic thymocyte proliferation 
was shown in the acute phase of the disease, in comparison to age-matched healthy individuals 
[36]. Similarly, relatively early in the progression of the disease in HAART-naïve individuals, TREC 
levels among peripheral CD4+ and CD8+ T cells and in the lymph nodes decrease, in comparison 
to age-matched healthy individuals [14]. In the absence of HAART, the thymus seems to be 
active during the infection, but only until peripheral CD4+ T cell numbers fall below 200 cells/μL 
(late stage disease), as measured by TREC frequency within CD4+ T cells [33]. 
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1.3.2. Immune Reconstitution under HAART: is the Thymus Part of the 
Business? 
The thymus has been shown to contribute for immune reconstitution after chemotherapy 
and bone-marrow transplantation [26, 30]. Likewise, rises in peripheral CD4+ T cell counts after 
HAART in HIV infected individuals are linked to regained thymic activity [14]. Meanwhile, a 
percentage of HIV infected individuals show poor reconstitution, regardless of viral suppression. 
One explanation put forward is impaired thymic activity [49]. So, it is imperative to understand 
the role the thymus is playing during HIV infection and immune reconstitution, especially among 
immunological non-responders. 
Although data regarding to negligible contribution of the thymus to reconstitution are also 
reported [13], several others have suggested a link between immune recovery and thymic activity 
after HAART. Indeed, thymic structure seems to recover upon HAART initiation, even after 
moderate to severe HIV disease before HAART [32, 34]. Correlations between thymic size and 
immune reconstitution, measured by increases in the absolute number of CD4+ T cells, were 
detected in HIV infected individuals [48]. Baseline thymic volume may also predict the magnitude 
of CD4+ T cell number recovery, in short and long-term HAART [46]. However, in another study, 
despite CT of one individual on HAART revealed the presence of thymic tissue two days before 
death, the immunohistological analysis of the thymus in the same patient after death showed 
absence of active thymopoiesis [13]. Therefore, correlations between thymus size and presence 
of thymic activity should be made with caution. Nevertheless, another report assessed thymic 
volume as predictor of CD4+ T cell loss after halting HAART, and individuals with bigger thymic 
volume presented a slower rate of CD4+ T cell drop after treatment interruption [47]. Additionally, 
thymic volume also correlated positively with the number of TRECs in CD4+ T cells in HIV 
infected individuals under HAART [34]. 
Actually, in what concerns TRECs, HIV infected individuals under HAART with lower 
thymic tissue have been shown to present lower numbers of CD4+ T cells bearing TRECs than 
the ones that have abundant thymic tissue, independently of age and duration of HAART [48]. In 
agreement, TREC levels have been shown to be increased in naïve CD4+ T cells after HAART, 
which indicates that the increase in the CD4+ T cell counts seems not to be due to the release of 
sequestered cells in the lymph nodes, but instead of RTEs output by the thymus [14]. Similarly, 
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sj/β TREC ratio was also shown to be increased after HAART, which suggests a thymopoietic 
contribution for immune reconstitution [36].  
A possible negative correlation between T cell repertoire perturbation and thymic size was 
also described in HIV infected individuals on HAART [48]. Individuals with minimal thymic tissue 
have a tendency to present reduced repertoire diversity, with a mean degree of perturbation of 
the CD4+ T cell repertoire higher than HIV-infected individuals with abundant thymic tissue [48]. 
CD31 expressing naïve T cells have been widely used as a correlate of thymic activity 
during HIV infection [37, 39, 40, 49]. A positive correlation was shown between the percentage 
of CD31+ naïve CD4+ T cells and thymic volume, percentage of naïve T cells, and with TREC 
frequency among CD4+ T cells [39]. The numbers of CD31bright naïve CD4+ T cells after one year 
of HAART were significantly increased. These cells were enriched in 80% more TREC numbers 
than CD31+ naïve T cells, meaning they are less proliferation experienced and have a more 
recent thymic origin [40]. Moreover, InR individuals also have less percentage of CD31+ naïve T 
cells than immunological responders (IR) after long-term HAART, setting impaired thymic output 
as a determinant of immune reconstitution failure [49]. 
1.4. Tregs in the Context of HIV Infection 
1.4.1. Tregs in the Immune System: What’s their Purpose?  
Tregs are key regulators of the immune system, and essential for the maintenance of 
homeostasis and prevalence of self-tolerance. If somehow any dysfunction inflicts this delicate 
equilibrium, immunopathology, allergy or even autoimmune illnesses may arise [50]. 
In humans, Tregs can be phenotypically characterized by the constitutive expression of 
CD25 (the IL-2 receptor-α) and by the master control gene forkhead-box transcription factor P3 
(Foxp3), which is responsible for Tregs differentiation and function on CD4+ T cells. More 
recently, CD127 (the IL-7receptor-α) has been also used to discriminate Tregs from conventional 
activated CD4+ T cells that can transiently express Foxp3 [50, 51]. 
There are two types of Treg, peripheral induced-Treg (iTreg) and naturally occurring Treg 
(nTreg) [52]. Concerning to nTreg, ontogenetically it was demonstrated that they are formed in 
the thymus, specifically in the double-positive stage of thymocyte development [53]. Functionally 
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they are both capable of suppressing proliferation, T cell priming, inhibit activation, induce 
cytolysis or apoptosis in a direct cell-to-cell contact fashion, or by producing cytokines [50].  
1.4.2. Regulatory T cells in Immune Reconstitution under HAART: Friends or 
Foes? 
The role of Tregs has been addressed in the context of several chronic viral infections, 
such as herpes simplex virus, hepatitis C virus and HIV [54]. With respect to HIV, since the 
immune system is subjected to a constant state of hyperactivation, due to the pro-inflammatory 
nature of HIV, an intricate balance between a fighting immune response and prevention of 
immunopathology may arise. Tregs seem to be crucial to modulate this equilibrium, but the role 
Tregs play in the setting of HIV infection is so far ill understood and controversial [51, 54]. On 
one hand, Tregs are reported to have detrimental impact by limiting HIV-specific CD8+ T cell 
responses and by promoting fibrosis in lymphoid tissues [15, 51]. On the other hand, Tregs 
seem also to have a beneficial effect dampening HIV-induced aberrant immune activation that 
results in immunopathology [51]. 
There is evidence that Tregs themselves are susceptible to be infected and depleted 
during HIV infection, presenting decreased peripheral numbers during HIV infection [54]. 
Nonetheless, the peripheral percentages of Treg seem to be augmented as disease progresses, 
with expansion of both naïve and memory subsets [55], and persist elevated even after HAART 
[39, 55, 56]. One of the advanced explanations is related to the increased production by the 
thymus of nTreg since a correlation between naïve Tregs numbers and TREC frequencies among 
CD4+ T cells was observed in a longitudinal assessment of HIV infected individuals under HAART 
[57]. In agreement with this observation, is a recent report showing increased frequencies of 
developing Tregs in thymuses of HIV infected individuals, in comparison to healthy controls [41]. 
Another report also shows that CD31 may mark Tregs as being from recent thymic origin in the 
context of HIV [39]. Using only Foxp3 to define Tregs, it was reported that the percentages of 
CD31+CD45RA+ Tregs are positively correlated with the sjTRECs content among CD4+ T cells 
and with numbers of circulating CD45RA+ CD4+ T cells, in HIV infected individuals under HAART 
[39]. On the contrary, a recent report showed that the percentages of Tregs, in individuals under 
HAART, seem to inversely correlate with both percentages and numbers of peripheral naïve 
CD4+ T cell, in particular in individuals with low level of reconstitution [58].  
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Both elevated Treg percentages and impaired thymic activity have been proposed as 
possible explanations for poor immune reconstitution [22, 23]. However, the relationship 
between these two factors and how they influence immune reconstitution during HIV infection 
remains to be elucidated.  
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2. Aims 
Thymic activity and Tregs play a role during the immune reconstitution of HIV infected 
individuals. However, the relationship between these parameters during immune reconstitution 
caresses of further clarification. Thus, the aim of this cross-sectional study in HIV infected 
individuals on HAART and with suppressed viral replication is to assess how thymic function and 
Tregs correlate with the quality of immune reconstitution and how much these two variables are 
associated with each other. More specifically, we will: 
 
1. Evaluate how the relationship between Tregs percentages and thymic activity 
correlates with the immune reconstitution; 
2. Assess the role of the thymus in Tregs output; 
3. Assess how Tregs and thymic activity influence immune reconstitution on the IR and 
InR reconstitution groups. 
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3. Material and Methods 
3.1. Study Participants 
In this cross-sectional study were enrolled 54 HIV infected individuals attending at the 
Hospital Joaquim Urbano (HJU), Centro Hospitalar do Porto (Porto, Portugal) (44 ± 8 years-old, 
range 31 to 62 years-old; 78% were males) under the following criteria: 1) infection with HIV-1; 2) 
receiving HAART for at least one year; 3) being on regular HAART compliance (with no history of 
irregular compliance on the past), and; 4) plasma viral loads below 50 copies of HIV RNA/mL. 
The study was approved by the ethics committee of HJU and the individuals were enrolled in the 
study after provided signed informed consent on volunteer basis. CD4+ T cell counts were 
obtained from a reference laboratory. CD4+ T cell count progression was calculated by 
subtracting baseline CD4+ T cell count (before HAART initiation) from the CD4+ T cell count at 
the moment of blood collection for each individual. 
3.2. Flow Cytometry Analysis 
Blood was collected to heparinized tube and processed for multiparametric flow 
cytometry analysis on the day of collection.  
3.2.1. RTEs Characterization 
200 μL of whole blood was incubated  for 15 min, at room temperature, with the 
following combination of monoclonal antibodies: PE-conjugated α-CD3 (clone OKT3), Pacific Blue-
conjugated α-CD8 (clone RPA-T8), FITC-conjugated α-CD45RA (clone HI100), PE-Cy7-conjugated 
α-CD31 (clone WM59; all purchased from Biolegend, San Diego, CA, USA) and APC-H7-
conjugated α-CD4 (clone RPA-T4, from BD Biosciences, San Jose, CA, USA). Afterwards, 
erythrocytes were removed upon for 15 min, at room temperature, in FACS Lysis Buffer (BD 
Biosciences, San Jose, CA, USA) and washed on FACS buffer. Each antibody was titrated using 
serial dilutions until the optimal concentration was determined. 
3.2.2. Tregs Characterization 
Peripheral blood mononuclear cells (PBMCs) were obtained by gradient centrifugation 
using Histopaque 1077 (Sigma-Aldrich, St. Louis, MO, USA) for 30 min, at room temperature, 
according to the manufacturer's instructions. Cells were collected, washed twice with sterile PBS 
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and enumerated using trypan blue exclusion dye. 2 million fresh PBMCs were cell surface 
stained upon incubation for 15 min, at room temperature, with V500-conjugated α-CD3 (clone 
UCHT1), APC-H7-conjugated α-CD4 (clone RPA-T4, both from BD Biosciences, San Jose, CA, 
USA), Pacific Blue-conjugated α-CD45RA (clone HI100), PE-Cy7-conjugated α-CD31 (clone 
WM59), PerCP-Cy5.5-conjugated α-CD127 (clone PHCD127) and APC-conjugated α-CD25 (clone 
BC96, all from Biolegend, San Diego, CA, USA). The intracellular staining of Foxp3 was 
performed using Foxp3 Staining Buffer Set from eBioscience (San Diego, CA, USA), accordingly 
to the manufature’s instructions using the PE-conjugated α-FOXP3 (clone PCH101, eBioscience, 
San Diego, CA, USA). Each antibody was titrated using serial dilutions until the optimal 
concentration was determined. 
3.2.3. Flow Cytometry Data Analysis 
All samples were acquired on a BD LSR II flow cytometer using FACS DIVA software and 
data were analyzed using FlowJo Software (Tree Star, OR, USA)  
3.3. Statistical Analysis 
The distribution of different variables was assessed for all individuals and in the different 
reconstitution groups by the Shapiro-Wilk normality test. Comparisons between the groups of Low 
and High %Tregs were made using Mann-Whitney’s test or unpaired t-test, depending on whether 
or not the variables have a normal distribution. Comparisons between the different reconstitution 
groups were made by using Mann-Whitney’s test or Kruskal-Wallis test followed Dunn multiple 
comparison tests. Spearman’s rank test was performed to assess correlations between two 
variables. The p - values were considered statistically significant when p < 0.05.  
The k-means cluster analysis was performed in the Statistical Package for the Social 
Sciences (SPSS) version 20 (IBM corporation, Armonk, New York). Individuals were clustered in 
two groups based on Tregs percentages, in which the distance between cluster centers of the two 
desired groups is maximized in an iterative process (maximum number of iterations set to 25) 
(Low %Tregs group, mean = 6.20; High %Tregs group, mean = 13.33). The two groups were 
named as individuals with Low %Tregs and High %Tregs, if they belong to the group with low or 
high percentages of Tregs, respectively (Tregs range on Table 3, section 4.3.).  
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4. Results 
4.1. A Novel Gating Strategy to Define Recent Thymic Emigrants (RTEs) 
The thymus has been shown to play a role during the immune reconstitution of HIV 
infected individuals, mainly subsequently to HAART initiation [49, 59]. In this regard, CD31 
expression among peripheral naïve CD45RA+CD4+ T cells has been associated with thymic 
activity in the setting of HIV infection [37, 39, 40, 49]. Although double-positive CD31+CD45RA+ 
cells have been used as a correlate of thymic activity, a report showed that CD31 is not 
necessarily lost during cell proliferation, namely during IL-7-induced proliferation [60]. This shows 
that some cells might maintain CD31 expression long time after leaving the thymus. Thus, some 
groups proposed to assess RTEs as naïve CD45RA+CD4+ T cells that express high levels of CD31 
and, in fact, the level of CD31 expression was strongly associated with higher TREC content in 
these cells, as compared with cells with dim to low expression of CD31 [37, 40].  
The gating strategy to select CD31+ CD45RA+CD4+ T cells is easy to define, but selecting 
CD31high CD45RA+CD4+ T cells is more complex, as it is not obvious where to set a threshold 
that clearly define CD31high from CD31+ cells. One gating strategy proposed by other authors to 
define CD31high naïve CD45RA+CD4+ T cells, as shown in Figure 10, selects the CD31+ T cells 
above the area of high density of cells among naïve CD45RA+CD4+ [37]. However, we noticed 
that the percentage of CD31highCD45RA+CD4+ T cells selected using this gating strategy seems 
to be influenced by the individual’s percentages of naïve CD45RA+CD4+ T cells. So, in an attempt 
to define RTEs in our study, we observed that monocytes, granulocytes, and the CD45RA- and 
CD45RA+ subsets of CD4+ T lymphocytes show different expression levels of CD31 both for 
healthy controls (Figure 11A) and for HIV infected individuals (Figure 11B)). 
 
Figure 10. Flow cytometry gating strategy used to select cells that express high levels of CD31 among naïve 
CD4+ T cells. RTE CD4 were selected among CD31+CCR7+CD45RA+CD4+ T cells, by gating cells that express high levels of 
CD31 above the area of high density of cells in a contour dot plot, as shown by the dashed black box [37]. 
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Figure 11. Different profiles of CD31 expression among CD4+ T lymphocytes, granulocytes and monocytes. In 
flow cytometry dot plots of whole blood samples from a representative healthy control (A) and from a representative HIV infected 
individual (B) we assessed the profile of CD31 expression on monocytes (green), granulocytes (orange) and on the CD45RA
-
 (red) 
and CD45RA+ (blue) subsets of CD4+ T cells. 
Monocytes are the cells with the highest level of CD31 expression followed, sequentially, 
by granulocytes, CD45RA+ CD4+ T lymphocytes and CD45RA- CD4+ T lymphocytes (Figure 11A 
and B), which has been previously shown in the literature [61, 62]. In addition, the profile and 
order by which each cell population express CD31 is very similar both for the healthy controls 
(Figure 11A) and for HIV infected individuals (Figure 11B). Additionally, we also observed a partial 
overlap between the peaks of CD31 expression of both granulocytes and CD45RA+CD4+ T cells. 
This observation prompted us to set a threshold to define CD31high cells among naïve 
CD45RA+CD4+ T cells, taking into account the CD31 expression among granulocytes. We defined 
the threshold (red line) for cells that express CD31 among granulocytes, tangentially to the area 
with higher density of cells, both for healthy controls (Figure 12A) and for HIV infected individuals 
(Figure 12B). Then, we applied this threshold to the CD4+ T cell compartment by plotting 
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CD45RA against CD31 to further identify CD31high cells (cells inside the red box). The peak of 
CD31 expression on CD31highCD45RA+CD4+ T cells as expected, laid between the peaks both 
CD45RA+CD4+ T cells and granulocytes for healthy controls (Figure 12A) and for HIV infected 
individuals (Figure 12B). 
 
 
Figure 12. Gating strategy defined to select CD31
high
CD45RA
+
CD4
+
 T cells (RTEs) in our study. CD31 expression 
among granulocytes was considered to define a threshold for selecting CD31highCD45RA+CD4+ T cells. A threshold (red line on 
the left dot plots from each panel) for cells that express CD31 among granulocytes was set near the area of high density of cells 
both for a healthy control (A) and for a HIV infected individual (B). This threshold was then applied to the CD4
+
 T cell 
compartment, and only cells that were CD45RA+CD31high on the right-side of threshold line were selected as RTEs (red box, 
middle plots from each panel). The peak of CD31 expression of these cells (black) laid between the peaks of both CD45RA+CD4+ 
T cells (blue) and granulocytes (orange) for the healthy control (right panel in A) and for the HIV infected individual (right panel in 
B). 
We consider that using this gating strategy could be advantageous since, by considering 
CD31 expression among granulocytes on a case by case basis, we would have an internal control 
for CD31 expression/staining for each individual. Moreover, the previously described gating 
strategy considers that all individuals have a defined population of CD31high cells, which should 
not be the case for individuals with no or minimal thymic output. In Figure 13 we show the novel 
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gating strategy defined by us, taking into account the expression of CD31 among granulocytes, in 
comparison to the one proposed by others earlier (Figure 10) [37]. 
 
 
       
 
 
 
         
Figure 13. Comparison between the two gating strategies. Representative analysis of CD31high RTEs for four HIV 
infected individuals with high (± 50%; A) and low (± 20%; B) percentages of naïve CD4+ T cells using the two gating strategies for 
each individual. The gating strategy define by us was based on the levels of CD31 expression on granulocytes (left panels) and the 
gating strategy previously reported [37] selects CD31high cells above the area with high density of CD45RA cells (right panels). 
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As can be seen, the different gating strategies yield very different percentages of 
CD31highCD45RA+CD4+ T cells for the same individual (Figure 13A and B). These different 
percentages of CD31high cells also proportionally represent very different percentages of 
CD31high cells among the CD31+CD45RA+CD4+ T cells, mainly for individuals with low 
percentages of naïve CD4+ T cells (Table 2). In this case, when the gating strategy is the one that 
selects CD31high cells above the area of high density of CD45RA+ cells, the CD31high cells 
represent more than 50% of CD31+ among naïve CD45RA+CD4+ T cells. Interestingly, this is the 
case for both individuals analyzed with low percentages of naïve CD45RA+CD4+ T cells (Table 2). 
Moreover, taking into consideration that the blood of all these individuals were stained for flow 
cytometry analysis on the same day, with the same mix of antibodies, the shift on the threshold 
to determine the CD31high is quite impressive among the individuals with low percentages of 
CD45RA+CD4+ T (Figure 13B). So, in this study we defined RTEs as CD31high cells among 
CD45RA+CD4+ T cells by taking into account CD31 expression on granulocytes for each 
individual, as an internal control. 
Table 2. Comparison of the percentages of RTE obtained by the two gating strategies. Respective age and 
percentages of CD45RA+, of CD31+CD45RA+, of CD31high and of CD31high among CD31+CD45RA+ cells for each patient 
analyzed in Figure 13. The ratios between the gating strategy using the area of high density of CD45RA+ cells (A) and the one that 
takes into consideration the granulocytes (B) is also shown. 
 
Gating Strategy 
(High Density of CD45RA
+ 
Cells) 
Gating Strategy 
(Granulocytes) 
Individual Age 
%CD45RA
+
 
CD4
+
 T 
cells 
%CD31
+
CD45RA
+ 
CD4
+
 T cells 
%CD31
high
 among 
CD31
+
CD45RA
+
 T 
cells 
%CD31
high 
CD45RA
+
CD4
+
 
T cells
 
%CD31
high
 among 
CD31
+
CD45RA
+
 T 
cells
 
%CD31
high 
CD45RA
+
CD4
+
 
T cells
 
1 62 47,23 23,84 30,95 7,38 3,86 0,92 
2 41 44,97 36,22 51,27 18,57 21,76 7,88 
3 39 22,56 12,47 66,55 8,30 3,93 0,49 
4 33 20,28 13,10 56,64 7,42 14,73 1,93 
 
4.2. Thymic Activity and Immune Reconstitution 
After defining a strategy for gating RTEs, we assessed how is thymic activity associated 
with the immune reconstitution of the HIV infected individuals on HAART from our cohort. We 
assessed not only the peripheral counts of CD31high CD45RA+CD4+ T cells but also of CD31+ 
CD45RA+CD4+ T cells (Figure 14), since double-positive cells have been previously used by the 
majority of the reports to assess thymic activity [39, 49]. As data shows, the increase in 
peripheral CD4+ T cell counts is positively correlated with both peripheral counts of CD31high (r = 
0.5056, p < 0.0001) (Figure 14A) and of CD31+ CD45RA+CD4+ T cells (r = 0.7905, p < 0.0001) 
(Figure 14B). Additionally, when assessing the peripheral CD4+ T cell counts progression during 
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HAART (calculated by subtracting from the count of CD4+ T cells at the moment of blood 
collection, the counts of CD4+ T cells at baseline), again a positive correlation is seen between 
both the peripheral counts of CD31high (r = 0.5096, p < 0.0001) (Figure 14C) and CD31+ 
CD45RA+CD4+ T cells (r = 0.6922, p < 0.0001) (Figure 14B). Curiously, while the correlation 
between the CD4+ counts and the CD31+CD45RA+CD4+ is quite linear, on the correlation with 
CD31high CD45RA+CD4+ cells the profile is quite different with a quite large spectrum of 
CD31high cells for individuals with more than 300 CD4+ T cells/µL. 
 
Figure 14. Thymic activity correlates with CD4+ T cell counts and CD4+ T cell counts progression during HAART 
in HIV infected individuals. CD4+ T cell counts were correlated with both peripheral counts of CD31high (A) and of CD31+ (B) 
CD45RA+ CD4+ T cells, parameters associated with thymic activity. Also CD4+ T cell count progression during HAART were 
correlated with both peripheral counts of CD31high (C) and of CD31+ (D) CD45RA+CD4+ T cells. Each diamond represents one 
individual and lines the correlation between the two variables. Correlations were evaluated by using Spearman’s rank correlation 
test coefficients. 
 
4.3. Tregs Percentages and Immune Reconstitution 
Previous results from our lab, in the this same cohort, showed that high percentages of 
peripheral Tregs, which were defined as CD127lowCD25highFoxp3+ expressing CD4+ T cells 
(Figure 15), were associated with poor immune reconstitution for individuals with low Nadir 
values (the lowest CD4+ T cell count achieved by each individual). In that work we defined the 
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threshold to separate the High %Tregs as >10% (Horta et al. manuscript submitted for 
publication).  
 
 
 
Figure 15. Gating strategy to define Tregs. Representative dot plots from an HIV infected individual illustrating the gating 
strategy for Treg analysis, by selecting first CD127
low
 cells within CD4
+
 T cells (A) and afterwards the CD25
high
Foxp3
+ 
cells (B). 
Tregs were considered as CD127lowCD25highFoxp3+ expressing CD4+ T cells. 
 
While the threshold of 10% fits very well our results and with data published by others, it 
was somehow defined ad-hoc. To determine a threshold in an unbiased fashion we performed a 
cluster analysis. To do so we used the program SPSS and specifically k-means cluster analysis, 
that divided our cohort in two populations one with low percentages of Tregs (from now on 
referred to as Low %Tregs) and the other with high percentages of Tregs (from now on referred to 
as High %Tregs) (Table 3). 
 
Table 3. Characteristics of both groups of Low and High %Tregs 
 n Tregs Range (%) 
Low %Tregs 38  3.02 – 9.15 
High %Tregs 16 9.95 – 18.73 
 
In agreement to what we previously described, we did not find a clear correlation between 
CD4+ T cell counts and the percentages of Tregs when considering overall individuals together (r 
= -0.2179, p = 0.1135) (Figure 16A). Moreover no difference was observed on the CD4+ T cell 
counts between the High and the Low %Tregs groups (p = 0.0900) (Figure 16B). We noticed, 
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however, a negative correlation between the CD4+ T cell counts and the percentages of Tregs 
only for the High %Tregs group (r = -0.6559, p = 0.0058) (Figure 16A).  
 
Figure 16. CD4+ T cell counts negatively correlate with high percentages of Tregs only for the High %Tregs 
group. CD4+ T cell counts were correlated with the percentages of Tregs for all the individuals (black), individuals from the High 
%Treg group (red) and from the Low %Treg group (blue) (A). The CD4+ T cell counts were compared in between the Low and High 
%Treg groups. Each diamond represents one individual and the lines the correlation between the two variables (A) or the median 
of the groups (B). Correlations were evaluated by using Spearman’s rank correlation test coefficients (A) and groups were also 
compared using Mann-Whitney’s test (B). 
 
As the individuals with the lowest CD4+ T cell counts belong to the High %Tregs group, we 
evaluated whether factors known to influence CD4+ T cell recovery [22, 23] were different 
between the Low and High %Treg groups. Namely, the Nadir value (Figure 17A), the baseline 
CD4+ T cell count before starting therapy (Figure 17B), the age of the individuals (Figure 17C) 
and years in therapy (Figure 17D) were assessed. Additionally we also assessed if there were 
differences between the groups in what refers to the CD4+ T cell progression during HAART (data 
not shown). No differences were found between the groups of Low and High %Tregs for these 
variables. However, when we look for potential correlations between these variables and the 
Tregs percentages, we found that the Nadir value (r = -0.5353, p = 0.0326) and the baseline 
CD4+ T cell count (r = -0.7441, p = 0.0009) are both negatively correlated with the percentage of 
Tregs, but solely for the group of High %Tregs (Table 4). 
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Figure 17. No differences for the Nadir values, baseline CD4+ T cell counts, age and years in therapy were 
observed between Low and High %Tregs groups. The Nadir values (A), baseline CD4+ T cell count before starting HAART 
(B), age of the individuals (C) and years in therapy (D) were compared in between the Low %Treg (blue) and High %Treg (red) 
groups. Each diamond represents one individual and the lines the median (A and D) or the mean (B and C) of the groups. Groups 
were compared using Mann-Whitney test (A and D) or unpaired t-test (B and C), depending on whether the variables had or not a 
normal distribution. 
 
Table 4. Matrix of correlations between the percentages of Tregs and the years in therapy, Nadir value, baseline 
CD4+ T cell count before starting HAART, the age (years) and the CD4+ T cell count progression during HAART. 
The correlations were made for both groups of Low %Tregs and High %Tregs. Correlations were evaluated by using Spearman’s 
rank correlation test coefficients. Both correlation coefficients and the respective p - values are indicated. 
 
 
Percentage of Tregs 
Low %Tregs 
group 
High %Tregs  
group 
Nadir value r = - 0.0957 
p = 0.5674 
r = - 0.5353 
p = 0.0326 
Baseline CD4+ T cell count r = - 0.0407 
p = 0.8083 
r = - 0.7441 
p = 0.0009 
Age (years) r = - 0.0517 
p = 0.7577 
r = 0.1180 
p = 0.6634 
Years in Therapy r = - 0.0165 
p = 0.9219 
r = - 0.4856 
p = 0.0565 
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4.4. Thymic Activity and Tregs Percentages During Immune Reconstitution 
Until now data from our cohort indicate that  on one hand thymic activity is positively 
associated to the immune reconstitution process in the HIV infected individuals and, on the other 
hand, high percentages of Tregs have an opposite association with immune restoration. Bearing 
this in mind we decided to evaluate in our cohort, the potential relationship thymic activity and 
the percentages of Tregs.  
 
Figure 18. High percentages of Tregs are negatively correlated with thymic activity. The peripheral counts of 
CD31
high
 (A) and CD31
+
 (B) CD45RA
+
CD4
+
 T cells were correlated with the percentages of Tregs for all the individuals (black), 
individuals from the High %Treg (red) and for the Low %Treg (blue) groups. The peripheral counts of CD31high (C) and CD31+ (D) 
CD45RA+CD4+ T cells were compared in between the Low and High %Treg groups. Each diamond represents one individual and 
the lines the correlation between the two variables (A and B) or the median of the group (C and D). Correlations were evaluated by 
using Spearman’s rank correlation test coefficients (A) and groups were also compared using Mann-Whitney’s test (B). 
Interestingly, for all HIV infected individuals, the percentages of Tregs are negatively 
correlated with both the peripheral counts of CD31high (r = -0.4081, p = 0.0022) (Figure 18A) 
and of CD31+ CD45RA+CD4+ T cells (r = -0.3069, p = 0.0240) (Figure 18B). We then assessed 
separately the groups of Low and High %Tregs. Strikingly, the High %Tregs individuals show a 
negative correlation between the percentages of Tregs and the peripheral counts of 
CD31highCD45RA+CD4+ T cells (r = -0.6706, p = 0.0045) but not the Low %Tregs individuals (r = 
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-0.2358, p = 0.1541) (Figure 18A). The same is also seen for the CD31+CD45RA+CD4+ T cells (r 
= -0.5647, p = 0.0227) (Figure 18B). Moreover, once individuals with High %Tregs show only a 
tendency to have lower peripheral counts of CD31+CD45RA+CD4+ T cells than individuals with 
Low %Tregs (p = 0.0647), among all the parameters compared between the groups of Low and 
High %Tregs, only a significant difference is seen in the peripheral counts of 
CD31highCD45RA+CD4+ T cells (p = 0.0271) (Figure 18C). 
We then checked if the relationship between both the peripheral counts of 
CD31highCD45RA+CD4+ T cells and of CD31+CD45RA+CD4+ T cells with the percentage of Tregs 
was affected by the Nadir value, the baseline CD4+ T cell count before starting therapy, the age 
of the individuals and the years in therapy (Table 5).  
Table 5. Matrix of correlations between the peripheral counts of CD31high and CD31+ CD45RA+CD4+ T cells 
with the Nadir value, baseline CD4+ T cell count before starting HAART, age, years in therapy the CD4+ T cell 
counts. The correlations were made for both groups of Low %Tregs and High %Tregs. Correlations were evaluated by using 
Spearman’s rank correlation test coefficients. Both correlation coefficients and the respective p - values are indicated. 
 
Peripheral CD31highCD45RA+CD4+ T cell counts, in the group of High %Tregs are 
positively correlated with the Nadir values (r = 0.6219, p = 0.0101) and CD4+ T cell counts (r = 
0.8198, p < 0.0001) and negatively correlated with the age of the individuals (r = -0.5230, p = 
0.0377). Interestingly, no correlations are seen among the Low %Tregs group. Regarding the 
peripheral CD31+CD45RA+CD4+ T cell counts in the group of High %Tregs, this parameter is 
positively correlated with the Nadir values (r = 0.7382, p = 0.0011), with years in therapy (r = 
0.5181, p = 0.0398) and with CD4+ T cells counts (r = 0.9265, p < 0.0001) whereas it is 
negatively correlated with the age of the individuals (r = -0.5221, p = 0.0380). In the group of 
Low %Tregs only CD4+ T cell counts (r = 0.7062, p < 0.0001) are positively correlated with 
CD31+CD45RA+CD4+ T cell counts. 
 
Low %Tregs group High %Tregs group 
CD31highCD45RA+ 
Counts 
CD31+CD45RA+ 
Counts 
CD31highCD45RA+ 
Counts 
CD31+CD45RA+ 
Counts 
Nadir value 
r = 0.0863 
p = 0.6066 
r = 0.2721 
p = 0.0984 
r = 0.6219 
p = 0.0101 
r = 0.7382 
p = 0.0011 
Baseline CD4
+
 T cell 
count 
r = 0.0608 
p = 0.7167 
r = 0.2688 
p = 0.1027 
r = 0.4623 
p = 0.0714 
r = 0.4882 
p = 0.0550 
Age (years) 
r = - 0.1831 
p = 0.2712 
r = - 0.1288 
p = 0.4409 
r = - 0.5230 
p = 0.0377 
r = - 0.5221 
p = 0.0380 
Years in Therapy 
r = 0.0256 
p = 0.8788 
r = 0.1474 
p = 0.3773 
r = 0.4848 
p = 0.0570 
r = 0.5181 
p = 0.0398 
CD4+ T cell counts r = 0.3156 
p = 0.0536 
r = 0.7062 
p < 0.0001 
r = 0.8198 
p < 0.0001 
r = 0.9265 
p < 0.0001 
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4.5. Thymic Export and Peripheral Tregs 
Peripheral Tregs may result from of thymic export (nTregs) or are induced in the 
periphery through the conversion of conventional CD4+ T cell into a Tregs cells (iTreg) [63]. To 
get some insight about the potential origin of Tregs, we analyzed the expression of CD31 and 
CD45RA among total CD4+ Tregs. For that, we quantified the peripheral counts of total CD4+ 
Tregs, CD31+CD45RA+ Tregs, CD45RA+CD4+ Tregs and of CD45RA-CD4+ Tregs in 28 HIV 
infected individuals, being 21 from the Low %Tregs and 7 from the High %Tregs groups (Figure 
19). The reduced number of individuals here is due to only 27 individuals having CD31 and 
CD45RA in the staining set as of Tregs.  
 
Figure 19. CD45RA- CD4+ Tregs are increased in High %Tregs individuals. The peripheral counts of Total CD4+ Tregs 
(A), CD31+CD45RA+CD4+ Tregs (B), CD45RA+CD4+ Tregs (C), and CD45RA-CD4+ Tregs (D) were compared between the Low 
%Treg and the High %Treg groups. Each diamond represents one individual and the lines the median of the group. All groups were 
compared using Mann-Whitney’s test. 
We saw no differences in the peripheral counts of total CD4+ Tregs (Figure 19A), of 
CD31+CD45RA+CD4+ Tregs (Figure 19B), and of CD45RA+CD4+Tregs (Figure 19C) between the 
groups of individuals with Low and High %Tregs. Interestingly, the results show a significant 
increase  in peripheral counts of CD45RA-CD4+ Tregs in individuals with High %Tregs, compared 
to individuals with Low %Tregs (p = 0.0496) (Figure 19D). We did not assess the counts of 
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CD31highCD45RA+ CD4+ Tregs since it was not possible to optimize the analysis of CD31high 
cells in PBMCs (necessary to perform the Foxp3 staining). 
4.6. Thymic Activity and Tregs in Different Immune Reconstitution Groups 
Despite the lack of consensus about what could be considered an incomplete immune 
reconstitution in the setting of HIV infection, we used a quite well established and used definition 
that states that individuals with a successful immune reconstitution should present CD4+ T cell 
counts above 500 cells/μL after 5 years on HAART [23, 64]. Corroborating this approach is the 
fact these individuals were shown to have morbidity and mortality rates comparable to those 
described for healthy individuals [65]. 
Bearing this in mind, we divided our cohort of HIV infected individuals in three different 
reconstitution groups, on the basis of their CD4+ T cell counts and time under therapy. Among 
the individuals under HAART for ≥5 years, the ones with CD4+ T cell counts ≥500 cells/μL were 
IR (n = 19), and those with peripheral CD4+ T cell counts <500 cells/μL were considered as 
InR(n = 15). The third group comprises the individuals under therapy for less than 5 years, 
regardless of the CD4+ T cell counts (< 5y, n = 20).  
Taking into account that high percentages of Tregs are associated to poor immune 
reconstitution and that it affects the counts of RTEs (defined as CD31highCD45RA+CD4+ T cells), 
we aimed to evaluate how these parameters were altogether associated with the immune 
reconstitution in these groups. 
Firstly, we assessed the counts of CD31high and of CD31+ CD45RA+CD4+ T cells on the 
IR, InR and <5y groups. No differences were observed between the reconstitution groups with 
respect to the peripheral counts of CD31highCD45RA+CD4+ T cells (Figure 20A). However, 
regarding the peripheral counts of CD31+CD45RA+CD4+  T cells, the IR group have significantly 
higher numbers of these cells in comparison with the <5y and InR groups (Figure 20B). 
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Figure 20. Evaluation of thymic activity in the three reconstitution groups. The peripheral counts of CD31high (A) and 
of CD31+ (B) CD45RA+CD4+ T cells were compared between the groups of immune reconstitution: >5y, IR and InR. Each 
diamond represents one individual and the lines the median of the group. All groups were compared using Kruskal-Wallis test 
followed by Dunn multiple comparison tests. 
Concerning to the percentages of Tregs, no differences are detected in between <5y, IR 
and InR individuals (Figure 21A) but a difference in CD4+ T cell counts progression is observed 
between the IR and the InR groups (Figure 21B). 
 
Figure 21. Evaluation of percentages of Tregs and of CD4+ T cell counts progression in the three groups of 
reconstitution. The percentages of Tregs (A) and the CD4
+
 T cell counts progression during HAART (B) were compared between 
the groups of immune reconstitution: >5y, IR and InR. Each diamond represents one individual and the lines the median of the 
group. All groups were compared using Kruskal-Wallis test followed by Dunn multiple comparison tests. 
Additonally we assessed if the reconstitution groups differ in other parameters known to 
influence the immune reconstitution as the Nadir value, the baseline CD4+ T cell count before 
starting therapy, the age of the individuals and the years in therapy. The results show that InR 
individuals have significantly lower Nadir values (Figure 22A) and baseline CD4+ T cell counts 
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before starting therapy (Figure 22B) than IR individuals. No differences are observed in terms of 
age (Figure 22C). The IR and the InR groups do not differ in terms of years in therapy but, as 
expected, both groups differ from the group of <5y in therapy (Figure 22D).  
 
Figure 22. Evaluation of Nadir values, baseline CD4+ T cell counts, age and years in therapy in the three groups 
of reconstitution. The Nadir values (A), the baseline CD4+ T cell counts (B), the age of the individuals (C) and the years in 
therapy (D) were compared between the groups of immune reconstitution: >5y, IR and InR. Each diamond represents one 
individual and the lines the median of the group. All groups were compared using Kruskal-Wallis test followed by Dunn multiple 
comparison tests. 
We observed that different groups of reconstitution have different median peripheral 
counts of CD31high and CD31+ naïve CD45RA+CD4+ T cells, but no differences are seen in terms 
of percentages of Tregs between the groups. Thus we evaluated the cellular ratios between the 
peripheral counts of Tregs and the counts of CD31highCD45RA+CD4+ (Figure 23A), of 
CD31+CD45RA+CD4+ (Figure 23B) and of total CD4+ T cells (Figure 23C) and saw no 
differences. Nevertheless, the InR group shows tendency to have higher ratios of Tregs counts 
with CD31+CD45RA+CD4+ counts and of total CD4+ T cell counts than the IR and <5y groups. 
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Figure 23. Evaluation of the cellular ratios in the three groups of reconstitution. The cellular ratios between the 
peripheral counts of Tregs and the counts of CD31highCD45RA+CD4+ (A), of CD31+CD45RA+CD4+ (B) and of total CD4+ T cells 
(C) were compared between the groups of immune reconstitution: >5y, IR and InR. Each diamond represents one individual and 
the lines the median of the group. All groups were compared using Kruskal-Wallis test followed by Dunn multiple comparison 
tests. 
Finally, to better understand if the percentages of Tregs were different among the 
individuals of reconstitution group, we divided the three groups of reconstitution in subgroups of 
Low and High %Tregs. We assessed first the peripheral counts of CD31high and 
CD31+CD45RA+CD4+ T cells for each subgroup of Low and High %Tregs (Figure 24). Data shows 
a significant difference in the peripheral counts of CD31highCD45RA+CD4+ T cells when 
comparing the Low and High %Tregs groups (p = 0.0067) (Figure 24A). No significant differences 
are seen within IR and InR groups in terms of counts of CD31highCD45RA+CD4+ T cells (Figure 
24A), and within <5y, the IR and InR groups in terms of peripheral counts of 
CD31+CD45RA+CD4+ T cells (Figure 24B). 
 
Figure 24. Evaluation of thymic activity in each subgroup of Low and High% Tregs within the three 
reconstitution groups. The peripheral counts of CD31
high
CD45RA
+
CD4
+
 T cells (A) and of CD31
+
CD45RA
+
CD4
+
 T cells (B), 
were compared in each subgroup of Low and High %Tregs within the groups of immune reconstitution: >5y, IR and InR. Each 
diamond represents one individual and the lines the median of the group. All groups were compared using Mann-Whitney test. 
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Regarding the CD4+ T cell counts progression after HAART, a significant difference is 
found between Low and High %Tregs subgroup within InR individuals (p = 0.0120) (Figure 25). 
 
 
Figure 25. Evaluation of CD4+ T cell counts progression after HAART in each subgroup of Low and High% Tregs 
within the three groups of reconstitution. The CD4+ T cell counts progression was compared in each subgroup of Low and 
High %Tregs within the groups of immune reconstitution of >5y, IR and InR. Each diamond represents one individual and the lines 
the median of the group. All groups were compared using Mann-Whitney test. 
 
Thereafter we sought again if other parameters such as the Nadir value, the baseline 
CD4+ T cell count before starting therapy, the age of the individuals and the years in therapy 
were influencing these results, after dividing the three groups in subgroups of Low and High 
%Tregs (Figure 26). No significant differences with respect to the Nadir values (Figure 26A), to 
the baseline CD4+ T cell counts before starting HAART (Figure 26B), to the age of the individuals 
(Figure 26C) and to years in therapy (Figure 26D) are found between Low and High %Tregs 
subgroups within each reconstitution group.  
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Figure 26. Evaluation of Nadir values, baseline CD4
+
 T cell counts, age and years in therapy in each subgroup of 
Low and High% Tregs within the three groups of reconstitution. The nadir values (A), the baseline CD4+ T cell counts 
(B), the age of the individuals (C) and the years in therapy (D) were compared in each subgroup of Low and High %Tregs within 
the groups of immune reconstitution: >5y, IR and InR. Each diamond represents one individual and the lines the median of the 
group. All groups were compared using Mann-Whitney test. 
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5. Discussion and Conclusions 
Impaired thymic activity and high percentages Tregs are among the proposed 
mechanisms to explain immune reconstitution failure in HIV infected individuals under HAART 
[22, 23]. However, the relationship between these two factors during immune reconstitution 
remains to be clarified and was the main subject of this thesis. Our results reveal that high 
percentages of Tregs are associated to low numbers of cells from a recent thymic origin. 
Furthermore, increased counts of Tregs seem to result from an accumulation of CD45RA-CD4+ 
Tregs counts in the periphery and not from recently produced Tregs from the thymus. 
5.1. A New Gating Strategy to Define RTEs 
We addressed thymic activity by quantifying the peripheral counts of CD31high 
CD45RA+CD4+ T cells. We felt the need to establish a new gating strategy/criteria to define 
RTEs. This need came from our observation that defining the CD31high for each individual simply 
by considering the higher expression of CD31 on naïve cells, is influenced by the percentages of 
naïve CD4 T cells of the individual. We looked for a gating strategy that would be independent of 
the degree of lymphopenia or T cell activation profile. Thus we made use of the fact that CD31 is 
expressed at distinct levels by different cell populations, and used specifically the granulocytes to 
set the limit to define high CD31 expression. This gating strategy is advantageous since we have 
an internal control for each individual that is independent of the percentages of naïve T cells that 
each individual has. The CD31highCD45RA+CD4+ T cell counts that we obtained were lower in 
comparison to those described for HIV infected individuals on HAART [40, 66]. Nonetheless, as 
CD31 is not necessarily lost after naïve T cell proliferation [60], by using this narrower gating 
strategy we believe that we select only the cells with high expression of CD31 among 
CD45RA+CD4+ T cells, which has been linked to a recent thymic origin [37, 40].  
Using this gating strategy we observed that the counts of CD31high cells seem to be 
independent from the percentages that each individual has of naïve CD45RA+CD4+ T cells, which 
somehow validated this gating strategy. However, further validation is crucial. To do so in the 
future we need to extend our analysis (our gating strategy and the one published previously) to a 
greater number of individuals, controls and HIV infected, and compare carefully the numbers 
obtained. Moreover we should perform TRECs quantification in sorted cells gated as 
CD31highCD45RA+CD4+ T cells using our gating strategy and the one published previously to 
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clearly establish/validate or not this gating strategy. In addition, this gating strategy should be 
applied to a longitudinal study with HIV individuals under HAART. In fact, all these approaches 
are ongoing presently in our laboratory. 
5.2. Immune reconstitution and Tregs – The Definition of Clusters 
In our analysis of Tregs we confirmed the data from our previous analysis that high 
percentages of Tregs (>10%) are associated to poor immune reconstitution, especially in 
individuals with low Nadir values (Horta et al. manuscript submitted for publication). In our 
previous analysis we defined a threshold of 10% to divide the individuals with High and Low 
percentage of Tregs, based on the increased number of HIV infected individuals with percentages 
of Tregs above 10%, compared to healthy controls. However, in the present study we performed a 
cluster analysis. The advantage of this type of analysis is that since Tregs percentages are so 
heterogeneous, cluster analysis divides all individuals into two more homogenous groups, yet 
different between them. This division is based on the distance between the means of Tregs 
percentages for each group. Interestingly, this analysis determined the division of all individuals 
to be very similar to our previous conclusion, since the first individual belonging to the group of 
High %Tregs has 9.95% of Tregs. The results obtained with this analysis are also similar to those 
obtained previously, which supports our previous division of Tregs > 10% as being associated 
with poor immune reconstitution (Horta et al. manuscript submitted for publication). 
5.3. Thymic Activity and Immune Reconstitution 
Low Nadir value is one of the most relevant parameters for the individuals with high Tregs 
percentage and incomplete immune reconstitution (Horta et al. manuscript submitted for 
publication). Since low Nadir values have been also linked to reduced thymic activity during 
reconstitution [24], we analyzed thymic activity in our cohort.   
As expected, we observed a clear positive correlation between both CD4+ T cell and CD4+ 
T cell counts progression with CD31+CD45RA+CD4+ T cell counts. Interestingly, when we 
considered the RTEs with our gating strategy we also observed positive correlations. However, as 
expected the correlations are not so clear-cut, which indicates that CD31high cells seem to be less 
dependent from the counts of CD4+ T cell counts, compared with CD31+ CD45RA+CD4+ T cells. 
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5.4. Tregs and Thymic Activity – Two (In)Dependent Factors Influencing Immune 
Reconstitution? 
We observed a direct correlation of high percentages of Tregs with low Nadir, low RTEs 
counts and poor immune reconstitution in the HIV infected individuals of our cohort. To our 
knowledge, our study is the first to show a direct association between high percentages of Tregs 
and low RTEs counts using CD31 as a correlate of thymic activity. Interestingly, a recent report 
showed an inverse correlation between percentages of Tregs (CD4+CD25highFoxp3+) and both 
percentages and numbers of naïve CD27+CD45RA+CD4+ T cells [58]. However, CD31 has been 
referred to be a better marker for assessment of thymic activity than CD27 itself, since CD31 
distinguishes two subpopulations within the naïve CD4+ T cell pool, one richer in TRECs (CD31+) 
and another that already underwent peripheral expansion and lacks CD31 [38, 45].  
As the thymus is known to export Tregs to the periphery, one hypothesis was that the 
thymus of these individuals was producing and/or exporting preferentially Tregs [41]. However, 
the analysis of our results do not support this possibility as no differences were observed in what 
concerns CD31+CD45RA+CD4+ Tregs and of CD45RA+CD4+ Tregs counts between individuals 
with Low and High %Tregs. Instead, we observe an increase in peripheral counts of CD45RA-
CD4+ Tregs in individuals with High %Tregs, in comparison to the group of Low %Tregs, despite 
no differences are seen when comparing total CD4+ Tregs counts between these groups.   
Taking into account all data, we could raise two hypotheses to explain the inverse 
association between Tregs and thymic activity. Tregs (Foxp3+CD4+ T cells) were reported to 
redistribute from lymphoid tissues and to proportionally increase in the peripheral blood after 
HAART initiation [67]. So, in the first hypothesis we could speculate that increased percentages 
of peripheral Tregs post HAART initiation could be linked to increased percentages of Tregs in the 
lymph nodes previous to HAART initiation. It is known that Tregs home to the secondary 
lymphoid tissues during HIV infection, which are niches of viral replication [15, 68]. To control 
viral replication and counteract immunopathology, Tregs produce TGF-β which has been 
implicated in collagen deposition and in structural alterations on lymph nodes. These structural 
alterations impede the access of T cells to IL-7, a key cytokine for T cell homeostasis which 
stimulate survival and proliferation of naïve T cells and among them, of RTEs [15]. This extensive 
damage on lymph nodes structure could be related to lower CD31high and CD31+ CD45RA+CD4+ 
T cell counts that we detected specifically in individuals with High %Tregs. In fact, fibrosis on 
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lymph nodes was described to be associated with depletion and reduced numbers of naïve CD4+ 
T cells during HIV infection [69, 70]. Thus it is possible that the survival of RTEs is affected due 
to defective access to stimuli on lymph nodes. In addition, the peripheral counts of CD4+ T cells 
were reported to be inversely correlated with the proportions of Tregs in lymphoid tissues in 
HAART-naïve HIV infected individuals. This supports our hypothesis and suggests that few 
lymphoid tissue proportions of Tregs are associated with adequate immunological recovery [67]. 
Secondly, it could be speculated that the relationship between impaired thymic activity 
and higher percentages of Tregs could be related to peripheral expansion of existing naïve and 
memory cells during immune reconstitution. In fact a report showed that, in a mouse model of 
lymphopenia-induced proliferation, naïve T cell proliferation is selectively inhibited by the action of 
regulatory T cells (Foxp3+CD25highCD4+) since it could lead to the emergence of pathogenic T 
cells [71]. As Tregs seem also to exert their function in a dose-dependent manner [72], 
peripheral expansion-mediated reconstitution in individuals with High %Tregs could be more 
affected. In fact individuals with High %Tregs show a tendency to have low CD4+ T cell counts in 
our study. In addition, the observation that individuals with High %Tregs have increased CD45RA-
CD4+ Tregs counts and a tendency to have higher total CD4+ Tregs counts in comparison to the 
group of Low %Tregs supports this hypothesis. This differences could be related to the peripheral 
conversion of conventional CD4+ T cell into Tregs [63], or only due to the already described 
preferential survival of Tregs promoted by HIV [51, 68]. In the future we could sort CD31high and 
CD31+ CD45RA+CD4+ T cells from both Low and High %Tregs individuals and perform a 
proliferative assay. We could stimulate the proliferation of cultured cells with Phytohaemagglutinin 
(PHA) in normal conditions, and quantify the expression of Ki67, to observe if cells from 
individuals with High %Tregs have lower rates of proliferation. 
5.5. Tregs and Thymic Activity in the Reconstitution Groups 
We divided the HIV infected individuals from our cohort in three reconstitution groups, 
according to their years in therapy and to their CD4+ T cell counts. For that, we took into 
consideration a used definition that establishes that individuals with a successful immune 
reconstitution should present CD4+ T cell counts above 500 cells/μL after 5 years on HAART 
[64]. Our results show that the InR group has significantly lower counts of CD31+CD45RA+CD4+ 
T cells in comparison to IR group and only a tendency is observe for the CD31highCD45RA+CD4+ 
T cell counts. In this case, we could raise two hypothesis. The first is related to the described 
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increased rates of cell proliferation among naïve (CD45RA+CD27+) CD4+ T cells reported for InR 
individuals, in comparison to IR individuals [73]. As CD31+CD45RA+CD4+ T cells are the progeny 
of CD31highCD45RA+CD4+ T cells following cell proliferation, in InR the latter could be induced to 
proliferate more probably due to their lower CD4+ T cell counts. Consistent with this hypothesis, 
are the similar levels of intrathymic proliferation that IR and InR were reported to have after 
estimation of the sj/βTREC ratio [73]; so it could be not thymic dysfunction but rather increased 
T cell division that is occuring in InR individuals [74]. In addition, InR were also reported to have 
higher activation levels in comparison to IR individuals, which could induce T cell proliferation 
and naïve-to-memory cell conversion [73]. Therefore, in this case we could assess if there are 
differences concerning to the state of immune activation in between IR and InR groups, by 
quantifying expression of HLA-DR and CD69 among CD4+ T cells, and particularly within the 
naïve CD45RA+CD4+ T cells. This could be linked to the tendency to increased Tregs percentages 
and to the lower numbers of CD31+CD45RA+CD4+ T cells seen in InR individuals.  
The second possibility could again be linked to collagen deposition on lymph nodes since 
this has been described as a limiting factor on immune reconstitution [69]. In this case, as RTEs 
have a deficient access to IL-7 and to other factors required for their survival on lymph nodes 
[15, 69], cell survival of CD31high and of CD31+ CD45RA+CD4+ T could be affected. Consistent 
with this hypothesis are the already reported higher cell-death rates of naïve CD4+ T cells in InR, 
in comparison with IR individuals [73]. This effect on survival that we hypothesize could be in 
turn related to the reduced CD4+ T cell counts progression that InR present, in comparison to the 
IR group. In fact, even among InR individuals, the ones with High %Tregs showed significantly 
reduced CD4+ T cell counts progression than individuals with Low %Tregs.  
We also observed that within individuals with less than <5 years of therapy, the ones with 
High %Tregs have lower peripheral counts of CD31highCD45RA+CD4+ T cells than individuals with 
Low %Tregs. This difference could rely on the fact that the thymus has a more prominent 
contribution for the immune reconstitution in the first years of treatment [59], and so the high 
percentages of Tregs could be influencing RTEs survival. In this case, we could quantify by flow 
cytometry 7-AAD in non-stimulated PBMCs of individuals from the <5y group, to assess if cell-
death rates of CD31high and CD31+ CD45RA+CD4+ T cells are higher in individuals with High 
%Tregs, compared to individuals with Low %Tregs. This assay could be also extended to the 
groups of IR and InR individuals, also to check if cell-death rates of CD31high and CD31+ 
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CD45RA+CD4+ T cells in individuals with High %Tregs are higher in comparison to individuals 
with Low %Tregs. 
Our study embraces some limitations, namely the reduced numbers of individuals in 
some groups of reconstitution, and also its cross-sectional nature which renders the 
establishment of a causal–effect relationship impossible. Nonetheless, here we shed light of 
some evidences regarding the role Tregs are playing in the setting of HIV infection, adding new 
variables to the already complex equation, in this case by adding thymic activity. Thus, further 
conclusions will necessarily involve a longitudinal follow-up in order to assess if Tregs are, in fact, 
affecting naïve T cells counts over time, and particularly of CD31high and CD31+CD45RA+CD4+ T 
cells. Understand this interaction could be crucial to further predict if the individuals will 
reconstitute properly or not the peripheral CD4+ T cell counts during HAART. 
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